Hepatic resections for colorectal metastases: the Italian multicenter experience

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Colorectal carcinoma frequently metastasizes to the liver, posing a significant challenge.
• Liver metastases are the primary site of relapse in a substantial number of colorectal cancer patients.
• Resectable hepatic metastases occur in a notable percentage of patients at initial diagnosis or develop later.

Purpose of the Study:

• To evaluate the efficacy and safety of surgical resection for liver metastases in colorectal cancer.
• To determine if hepatic resection improves survival outcomes compared to non-surgical management.
• To establish surgical resection as a potential curative treatment for selected patients with colorectal cancer liver metastases.

Main Methods:

• Review of recent experiences and multicenter surveys on surgical treatment of colorectal cancer liver metastases.
• Analysis of survival data comparing resected versus unresectable hepatic metastases.
• Comparison of outcomes with adjuvant therapies like chemotherapy and radiation therapy.

Main Results:

• Hepatic resection is increasingly accepted as a safe and effective therapy for colorectal cancer liver metastases.
• Surgical treatment offers the best survival prospect for carefully selected patients.
• Median survival for resected patients ranges from 6-12 months, with 5-year survival rates between 20-40% in various studies.
• A multicenter survey reported a 33% 5-year survival rate in 859 resected patients.

Conclusions:

• Surgical resection is the treatment of choice for technically resectable liver metastases from colorectal cancer.
• Resection provides significant survival prolongation compared to non-surgical management for unresectable metastases.
• Despite the lack of prospective randomized trials, surgical intervention offers the best hope for cure in selected patients.